Search Results

You are looking at 1 - 10 of 866 items for :

  • Refine by Access: All x
Clear All
Full access

Targeted Therapy in Relapsed Classical Hodgkin Lymphoma

Shira Dinner and Ranjana Advani

/print certificate. Release date: August 22, 2013; Expiration date: August 22, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Describe the rationale for targeted therapy in patients with relapsed classical HL

Full access

Management of Relapsed and Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson, and Paul G. Richardson

ultimately experience relapse and require further therapy. Prognosis associated with relapsed MM is generally poor, with a median overall survival of less than 1 year among patients who have received 2 or more prior lines of therapy. 20 Definition of

Full access

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover

brain, and less frequently to bone. 2 , 3 Understanding the determinants of distant relapse is critical because survival for patients with TNBC after metastatic diagnosis ranges from 17 3 , 4 to 25 months. 5 Most metastatic recurrences of TNBC occur

Full access

Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease

Presented by: Matthew J. Matasar

With only approximately half of patients eligible to receive curative autologous stem cell transplant (ASCT), outcomes remain poor for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). At the NCCN 2021 Virtual

Full access

Evolution of Therapy for Relapsed/Refractory Multiple Myeloma

Jorge J. Castillo

Numerous advances have recently been made in the treatment of relapsed/refractory (R/R) multiple myeloma (MM): novel immunomodulators, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, and nuclear export inhibitors have

Full access

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz

performance status, multiple comorbidities, inability to tolerate chemotherapy, and multidrug resistance. 2 The management of patients with relapsed/refractory AML remains a huge clinical challenge with few therapeutic options available, particularly for

Full access

Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease

Presented by: Mazyar Shadman

Despite advancements in treatment, mantle cell lymphoma (MCL) is still considered incurable, and most patients experience relapsed/refractory (R/R) disease. However, according to Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research

Full access

Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma

Yongzhu He, Laihui Luo, Renfeng Shan, Junlin Qian, Lifeng Cui, Zhao Wu, Shuju Tu, WenJian Zhang, Wei Lin, Hongtao Tang, Zeyu Huang, Zhigang Li, Shengping Mao, Hui Li, Zemin Hu, Liping Liu, Wei Shen, Kun He, and Yong Li

significant challenge in the management of this disease. 2 – 4 According to the time of tumor recurrence after surgery, it can be divided into early relapse and late relapse. Early relapse may be the result of an initial occult tumor metastasis, whereas late

Full access

Role of Routine Imaging in Lymphoma

Nina D. Wagner-Johnston and Nancy L. Bartlett

patients with relapsed lymphoma can be cured with autologous stem cell transplant, led to the adoption of CT for monitoring patients for early relapse. The frequency with which CT was used in the posttreatment setting largely mimicked the interval adopted

Full access

Management of Recurrent Small Cell Lung Cancer

Bryan J. Schneider

supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer . J Clin Oncol 2006 ; 24 : 5441 – 5447 . 2. Postmus PE Berendsen HH van Zandwijk . Retreatment with the induction regimen in small